Mast Cell Activation Syndrome Diagnosis and Management

Diagnostic Testing

Serum tryptase level should be measured, with levels >15 ng/mL supporting systemic mastocytosis and warranting bone marrow examination, as recommended by the National Comprehensive Cancer Network 1, 2
Bone marrow aspirate and biopsy is indicated given the clinical suspicion, with flow cytometry, immunohistochemistry, cytogenetics, and molecular testing for KIT D816V mutation by allele-specific PCR, as recommended by the National Comprehensive Cancer Network 1
KIT D816V mutation testing should be performed on peripheral blood using allele-specific quantitative PCR (ASO-qPCR), which is highly sensitive and can detect the mutation found in >80% of adult systemic mastocytosis cases, according to Leukemia research 3, 4
If KIT D816V is negative, complete KIT gene sequencing should be performed on bone marrow samples, as other mutations can occur, as noted in Leukemia studies 3, 4
24-hour urine for histamine metabolites and prostaglandin D2 can support the diagnosis, as mentioned in Leukemia research 4
Comprehensive metabolic panel with uric acid, LDH, and liver function tests are essential for staging, as recommended by the National Comprehensive Cancer Network 1
CT/MRI or ultrasound of abdomen/pelvis to evaluate for organomegaly, as recommended by the National Comprehensive Cancer Network 1
DEXA scan to evaluate for osteopenia/osteoporosis, which is common in systemic mastocytosis, as recommended by the National Comprehensive Cancer Network 1

Fasting blood glucose and hemoglobin A1c are mandatory to screen for diabetes mellitus, the most common cause of peripheral neuropathy, as recommended by Praxis Medical Insights 5, 6
Vitamin B12 with metabolites should be checked, particularly given the MTHFR abnormalities, as recommended by Praxis Medical Insights 5, 6
Serum protein electrophoresis with immunofixation to evaluate for monoclonal gammopathy, as recommended by Praxis Medical Insights 5, 6
HIV and hepatitis B/C screening when clinically indicated, as recommended by Praxis Medical Insights 5, 6
Anti-myelin-associated glycoprotein (anti-MAG) antibodies for sensory peripheral neuropathies, as recommended by Praxis Medical Insights 5, 6
Electrodiagnostic studies to differentiate between axonal and demyelinating neuropathies, as recommended by Praxis Medical Insights 5, 6

Morning serum total testosterone should be confirmed with repeat testing due to assay variability, as recommended by Clinical Infectious Diseases 7
Free testosterone measurement using equilibrium dialysis or calculated free androgen index is needed, as recommended by Clinical Infectious Diseases 7
Luteinizing hormone (LH) and follicular stimulating hormone (FSH) should be measured to determine if hypogonadism is primary or central, as recommended by Clinical Infectious Diseases and The Journal of Urology 7, 8
Do not prescribe exogenous testosterone therapy as this will suppress spermatogenesis and impair fertility, as recommended by The Journal of Urology 8

Anti-mediator drug therapy should be initiated with H1 and H2 antihistamines, as recommended by the National Comprehensive Cancer Network 1, 2
Consider cromolyn sodium for gastrointestinal symptoms if present, as recommended by the National Comprehensive Cancer Network 1
Leukotriene inhibitors may be beneficial, as recommended by the National Comprehensive Cancer Network 1
Patients should be counseled about potential triggers, as recommended by the National Comprehensive Cancer Network 1, 2
Epinephrine auto-injector should be prescribed given the history of edema and risk of anaphylaxis, as recommended by the National Comprehensive Cancer Network 2

Never start testosterone replacement therapy in this patient without first determining the cause of hypogonadism and discussing fertility implications, as recommended by The Journal of Urology 8
Do not dismiss the mast cell activation diagnosis based on only one positive marker; bone marrow evaluation is essential for definitive diagnosis, as recommended by the National Comprehensive Cancer Network and Leukemia research 1, 3
Avoid known mast cell degranulators including certain opioids, NSAIDs, and contrast agents without premedication, as recommended by the National Comprehensive Cancer Network 2

Serum tryptase and KIT D816V ASO-qPCR should be monitored at regular intervals to assess disease activity, as recommended by Leukemia research 4
Clinical assessment every 6-12 months with comprehensive metabolic panel, CBC, and symptom assessment using validated tools, as recommended by the National Comprehensive Cancer Network and Leukemia research 1, 4